View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
April 16, 2021

LoA Update: Chengdu Kanghong Pharmaceuticals’ Phase III ophthalmic agent drops 7 points in AMD after trial stop

The likelihood of approval (LoA) of Chengdu Kanghong Pharmaceuticals’ (SHE:002773) Phase III conbercept in neovascular age-related macular degeneration (AMD) dropped 7 points as of 12 April, according to GlobalData’s LoA data.

By Sean Rai-Roche

The likelihood of approval (LoA) of Chengdu Kanghong Pharmaceuticals’ (SHE:002773) Phase III conbercept in neovascular age-related macular degeneration (AMD) dropped 7 points as of 12 April, according to GlobalData’s LoA data. The drop came as the company said on 9 April the Phase III PANDA-1 (NCT03577899) trial will stop.

The statement noted that global health emergencies and changes in external environments had caused great difficulties for the clinical research as large numbers of the 1,140 patients have stopped treatment, missed follow-ups, and exceeded testing windows. The number of cases tested for the dosing regimen is now less than 40% of the enrolled cases, it said. The trial has been unable to obtain results with registrational value, it added.

The vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) inhibitor had an LoA of 37% for AMD. Based on GlobalData’s analysis using a combination of machine learning and a proprietary algorithm, the LoA has dropped to 30%. Conbercept prevents VEGF and its endothelial cell surface receptor binding, blocking its biological activity and inhibiting endothelial cell proliferation and angiogenesis.

Sean Rai-Roche is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena